ABOUT METABOLICA

We didn’t build a probiotic. We built a roadmap.

Metabolica Health is a research-forward bioscience company innovating in the fields of nutraceuticals, probiotics and pharmaceuticals. Our approach is inspired by the microbiome:  Probiotics that change the architecture of the gut microbiome and are designed to optimize the production of health-promoting bioactive compounds; and drug candidates that are supercharged enhanced versions of naturally occurring microbiome metabolites.

Our most advanced drug project is focussed on restoring and improving the body’s ability to produce insulin and rebalance metabolism. Unlike current treatments, such as GLP-1 agonists, our approach directly targets the health and function of the pancreas and well as the capacity of cells to respond to insulin. By targeting the disease's biological root, the Metabolica approach regenerates insulin-producing pancreatic β-cells and enhances systemic metabolism. This will lead to weight loss, improved liver health and glucose management.

Backed by peer-reviewed publications, patents in the United States, Canada and the European Union, and global academic partnerships including the University of Paris and Kyoto University, Metabolica is building a scalable therapeutic platform with broad clinical potential and clear translational focus.

In addition to ACREOS™, our drug discovery and development program, we are concurrently developing science based first-in-class next generation probiotic and postbiotic natural health products for applications in metabolic health and other areas.

Metabolica is also advancing holistic nutriceutical plus probiotic products to ensure that the best research-backed approaches are available in a single powerful format for those seeking natural products to support metabolic health, stress resilience, and other areas.  The first release of these products is scheduled for Q4 2026.

Our leadership team and science advisory board combine deep scientific expertise with operational and business experience to translate discovery into real-world impact.

WHAT WE BELIEVE

Precision is the floor. Not the ceiling.

01

Name what's in the bottle.

Genus, species, strain ID. On every label. No proprietary blends. No “probiotic complex.”

02

Dose what the studies dosed.

Not the marketing CFU. Not the minimum-viable CFU. The number the published trials used.

03

Cite every claim.

Every health statement traces back to a peer-reviewed mechanism. Tagged on the page. Linked to the paper.

THE ROADMAP

Where we are. Where we’re going.

Phase 01 · Now

Bundle stack logic.

Advisory board public, first study published, three formulations defined.

Phase 02 · Q4 2026

Resilio 24™ and ReShape™ launch.

Built around how your microbiome keeps time.

Phase 03 · Q1 2027

Lucid Calm™ launch.

Metabolic balance and stress resilience round out the three-ritual stack.

Phase 04 · Q2 2027

Practitioner channel.

Canada NPN expansion. Wholesale to clinics and integrative practices.

LEADERSHIP

Board of Directors

The leaders steering Metabolica's strategy and governance.

Howard Fields

Howard Fields

Metabolica Health Inc. · CEO, PRESIDENT & DIRECTOR

Daniel Auld, Ph.D.

Daniel Auld, Ph.D.

Metabolica Health Inc. · EVP, CHIEF SCIENCE OFFICER & DIRECTOR

Roy Bonnell

Roy Bonnell

Metabolica Health Inc. · DIRECTOR & CHAIRMAN